Clinical Proteomics:Article Title: Depletion of central memory CD8 + T cells might impede the antitumor therapeutic effect of Mogamulizumab
Article Snippet: CyTOF: 141Pr- EOMES, Fluidigm, WD1928, Custom made 142Nd- CD40, Fluidigm, 5C3, 3142010B 143Nd- CD45RA, Fluidigm, HI100, 3143006B 146Nd- CD8a, Fluidigm, RPA-T8, 3146001B 147Sm- CD11c, Fluidigm, Bu15, 3147008B 148Nd- CD14, Fluidigm, RMO52, 3148010B 149Sm- pLck [T505], Fluidigm, 4/LCK-Y505, Custom made 150Nd- CD134 (OX40), Fluidigm, ACT35, 3150023B 151Eu- CD107a (LAMP1), Fluidigm, H4A3, 3151002B 153Eu- CD194 (CCR4), Fluidigm, 205410, 3153013A 154Sm- CD3, Fluidigm, UCHT1, 3154003B 155Gd- CD279 (PD-1), Fluidigm, EH12.2H7, 3155009B 156Gd- CD86, Fluidigm, IT2.2, 3156008B 158Gd- pStat3 [Y705], Fluidigm, 4, 3158005A 159Tb- FoxP3, Fluidigm, 236A/E7, Custom made 160Gd- Tbet, Fluidigm, 4B10, 3160010B 161Dy- CD152 (CTLA-4), Fluidigm, 14D3, 3161004B 162Dy- CD80 (B7-1), Fluidigm, 2D10.4, 3162010B 163Dy- CD183 (CXCR3), Fluidigm, G025H7, 3163004B 164Dy- CD185 (CXCR5), Fluidigm, 51505, 3164016B 3 n atu re p o rtfo lio | rep o rtin g su m m ary M a rch 2021 Validation Eukaryotic cell lines Policy information about cell lines Cell line source(s) Authentication Mycoplasma contamination Commonly misidentified lines (See ICLAC register) Animals and other organisms Policy information about studies involving animals; ARRIVE guidelines recommended for reporting animal research Laboratory animals Wild animals Field-collected samples Ethics oversight Note that full information on the approval of the study protocol must also be provided in the manuscript.
Article Title: Visualization of Mass Cytometry Signal Background to Enable Optimal Core Panel Customization and Signal Threshold Gating.
Article Snippet: Signal interference or overlap in mass cytometry is minimal compared to flow cytometry but must still be considered for optimal panel design and assay sensitivity.. Here we describe a procedure for evaluating signal interference dynamics in the context of a 25-parameter core immunophenotyping panel.. Specifically, a massminusmany (MMM) approach was used to assess background signals in “empty” or “blank” channels intended for further customization.
Article Title: Early-to-mid stage idiopathic Parkinson’s disease shows enhanced cytotoxicity and differentiation in CD8 T-cells in females
Article Snippet: Metal Isotope, Antibody, Clone, Manufacturer, Catalogue# 89Y, CD45, HI30, Fluidigm (now Standardbio), Part of MDIPA (cat. 201325) 103Rh, Live/Dead indicator, Fluidigm, Part of MDIPA, 201325 141Pr, CD196 (CCR6), G034E3, Fluidigm, Part of MDIPA, 201325 142Nd, CD117 (c-kit)*, 104D2, Biolegend, 313223 143Nd, CD123, 6H6 ,Fluidigm, Part of MDIPA, 201325 144Nd, CD19, HIB19, Fluidigm, Part of MDIPA, 201325 145Nd, CD4, RPA-T4, Fluidigm, Part of MDIPA, 201325 146Nd, CD8a, RPA-T8, Fluidigm, Part of MDIPA, 201325 147Sm, CD11c, Bu15, Fluidigm, Part of MDIPA, 201325 148Nd, CD16, 3G8, Fluidigm, Part of MDIPA, 201325 149Sm, CD45RO, UCHL1, Fluidigm, Part of MDIPA, 201325 150Nd, CD45RA, HI100, Fluidigm, Part of MDIPA, 201325 151Eu, CD161, HP-3G10, Fluidigm, Part of MDIPA, 201325 152Sm, CD194 (CCR4), L291H4, Fluidigm, Part of MDIPA, 201325 153Eu, CD25, BC96, Fluidigm, Part of MDIPA, 201325 154Sm, CD27, O323, Fluidigm, Part of MDIPA, 201325 155Gd, CD57, HCD57, Fluidigm, Part of MDIPA, 201325 156Gd, CD183 (CXCR3), G025H7, Fluidigm, Part of MDIPA, 201325 158Gd, CD185 (CXCR5), J252D4, Fluidigm, Part of MDIPA, 201325 159Tb, KLRG1*, SA231A2, Biolegend, 367702 160Gd, CD28, CD28.2, Fluidigm, Part of MDIPA, 201325 161Dy, CD38, HB-7, Fluidigm, Part of MDIPA, 201325 162Dy, CD336 (NKP44)*, P44-8, Biolegend, 325102 163Dy, CD56 (NCAM), NCAM16.2, Fluidigm, Part of MDIPA, 201325 164Dy, TCRgd, B1, Fluidigm, Part of MDIPA, 201325 165Ho, CD223 (LAG3), 11C3C65, Fluidigm, 3165037B 166Er, CD294, BM16, Fluidigm, Part of MDIPA, 201325 167Er, CD197 (CCR7), G043H7, Fluidigm, Part of MDIPA, 201325 168Er, CD14, 63D3, Fluidigm, Part of MDIPA, 201325 169Tm, CD49d*, 9F10, Biolegend, 304302 170Er, CD3, UCHT1, Fluidigm, Part of MDIPA, 201325 171Yb, CD20, 2H7, Fluidigm, Part of MDIPA, 201325 172Yb, CD66b, G10F5, Fluidigm, Part of MDIPA, 201325 173Yb, HLA-DR, LN3, Fluidigm, Part of MDIPA, 201325 174Yb, IgD, IA6-2, Fluidigm, Part of MDIPA, 201325 175Lu, CD279 (PD-1), EH12.2H7, Fluidigm, 3175008B, 201325 176Yb, CD127, A019D5, Fluidigm, Part of MDIPA, 201325 * in-house conjugation using Maxpar X8 Antibody Labeling Kits MDIPA (201325, Fluidigm).
Recombinant:Article Title: Depletion of central memory CD8 + T cells might impede the antitumor therapeutic effect of Mogamulizumab
Article Snippet: CyTOF: 141Pr- EOMES, Fluidigm, WD1928, Custom made 142Nd- CD40, Fluidigm, 5C3, 3142010B 143Nd- CD45RA, Fluidigm, HI100, 3143006B 146Nd- CD8a, Fluidigm, RPA-T8, 3146001B 147Sm- CD11c, Fluidigm, Bu15, 3147008B 148Nd- CD14, Fluidigm, RMO52, 3148010B 149Sm- pLck [T505], Fluidigm, 4/LCK-Y505, Custom made 150Nd- CD134 (OX40), Fluidigm, ACT35, 3150023B 151Eu- CD107a (LAMP1), Fluidigm, H4A3, 3151002B 153Eu- CD194 (CCR4), Fluidigm, 205410, 3153013A 154Sm- CD3, Fluidigm, UCHT1, 3154003B 155Gd- CD279 (PD-1), Fluidigm, EH12.2H7, 3155009B 156Gd- CD86, Fluidigm, IT2.2, 3156008B 158Gd- pStat3 [Y705], Fluidigm, 4, 3158005A 159Tb- FoxP3, Fluidigm, 236A/E7, Custom made 160Gd- Tbet, Fluidigm, 4B10, 3160010B 161Dy- CD152 (CTLA-4), Fluidigm, 14D3, 3161004B 162Dy- CD80 (B7-1), Fluidigm, 2D10.4, 3162010B 163Dy- CD183 (CXCR3), Fluidigm, G025H7, 3163004B 164Dy- CD185 (CXCR5), Fluidigm, 51505, 3164016B 3 n atu re p o rtfo lio | rep o rtin g su m m ary M a rch 2021 Validation Eukaryotic cell lines Policy information about cell lines Cell line source(s) Authentication Mycoplasma contamination Commonly misidentified lines (See ICLAC register) Animals and other organisms Policy information about studies involving animals; ARRIVE guidelines recommended for reporting animal research Laboratory animals Wild animals Field-collected samples Ethics oversight Note that full information on the approval of the study protocol must also be provided in the manuscript.
Article Title: Visualization of Mass Cytometry Signal Background to Enable Optimal Core Panel Customization and Signal Threshold Gating.
Article Snippet: Signal interference or overlap in mass cytometry is minimal compared to flow cytometry but must still be considered for optimal panel design and assay sensitivity.. Here we describe a procedure for evaluating signal interference dynamics in the context of a 25-parameter core immunophenotyping panel.. Specifically, a massminusmany (MMM) approach was used to assess background signals in “empty” or “blank” channels intended for further customization.
Article Title: Early-to-mid stage idiopathic Parkinson’s disease shows enhanced cytotoxicity and differentiation in CD8 T-cells in females
Article Snippet: Metal Isotope, Antibody, Clone, Manufacturer, Catalogue# 89Y, CD45, HI30, Fluidigm (now Standardbio), Part of MDIPA (cat. 201325) 103Rh, Live/Dead indicator, Fluidigm, Part of MDIPA, 201325 141Pr, CD196 (CCR6), G034E3, Fluidigm, Part of MDIPA, 201325 142Nd, CD117 (c-kit)*, 104D2, Biolegend, 313223 143Nd, CD123, 6H6 ,Fluidigm, Part of MDIPA, 201325 144Nd, CD19, HIB19, Fluidigm, Part of MDIPA, 201325 145Nd, CD4, RPA-T4, Fluidigm, Part of MDIPA, 201325 146Nd, CD8a, RPA-T8, Fluidigm, Part of MDIPA, 201325 147Sm, CD11c, Bu15, Fluidigm, Part of MDIPA, 201325 148Nd, CD16, 3G8, Fluidigm, Part of MDIPA, 201325 149Sm, CD45RO, UCHL1, Fluidigm, Part of MDIPA, 201325 150Nd, CD45RA, HI100, Fluidigm, Part of MDIPA, 201325 151Eu, CD161, HP-3G10, Fluidigm, Part of MDIPA, 201325 152Sm, CD194 (CCR4), L291H4, Fluidigm, Part of MDIPA, 201325 153Eu, CD25, BC96, Fluidigm, Part of MDIPA, 201325 154Sm, CD27, O323, Fluidigm, Part of MDIPA, 201325 155Gd, CD57, HCD57, Fluidigm, Part of MDIPA, 201325 156Gd, CD183 (CXCR3), G025H7, Fluidigm, Part of MDIPA, 201325 158Gd, CD185 (CXCR5), J252D4, Fluidigm, Part of MDIPA, 201325 159Tb, KLRG1*, SA231A2, Biolegend, 367702 160Gd, CD28, CD28.2, Fluidigm, Part of MDIPA, 201325 161Dy, CD38, HB-7, Fluidigm, Part of MDIPA, 201325 162Dy, CD336 (NKP44)*, P44-8, Biolegend, 325102 163Dy, CD56 (NCAM), NCAM16.2, Fluidigm, Part of MDIPA, 201325 164Dy, TCRgd, B1, Fluidigm, Part of MDIPA, 201325 165Ho, CD223 (LAG3), 11C3C65, Fluidigm, 3165037B 166Er, CD294, BM16, Fluidigm, Part of MDIPA, 201325 167Er, CD197 (CCR7), G043H7, Fluidigm, Part of MDIPA, 201325 168Er, CD14, 63D3, Fluidigm, Part of MDIPA, 201325 169Tm, CD49d*, 9F10, Biolegend, 304302 170Er, CD3, UCHT1, Fluidigm, Part of MDIPA, 201325 171Yb, CD20, 2H7, Fluidigm, Part of MDIPA, 201325 172Yb, CD66b, G10F5, Fluidigm, Part of MDIPA, 201325 173Yb, HLA-DR, LN3, Fluidigm, Part of MDIPA, 201325 174Yb, IgD, IA6-2, Fluidigm, Part of MDIPA, 201325 175Lu, CD279 (PD-1), EH12.2H7, Fluidigm, 3175008B, 201325 176Yb, CD127, A019D5, Fluidigm, Part of MDIPA, 201325 * in-house conjugation using Maxpar X8 Antibody Labeling Kits MDIPA (201325, Fluidigm).
Staining:Article Title: Depletion of central memory CD8 + T cells might impede the antitumor therapeutic effect of Mogamulizumab
Article Snippet: CyTOF: 141Pr- EOMES, Fluidigm, WD1928, Custom made 142Nd- CD40, Fluidigm, 5C3, 3142010B 143Nd- CD45RA, Fluidigm, HI100, 3143006B 146Nd- CD8a, Fluidigm, RPA-T8, 3146001B 147Sm- CD11c, Fluidigm, Bu15, 3147008B 148Nd- CD14, Fluidigm, RMO52, 3148010B 149Sm- pLck [T505], Fluidigm, 4/LCK-Y505, Custom made 150Nd- CD134 (OX40), Fluidigm, ACT35, 3150023B 151Eu- CD107a (LAMP1), Fluidigm, H4A3, 3151002B 153Eu- CD194 (CCR4), Fluidigm, 205410, 3153013A 154Sm- CD3, Fluidigm, UCHT1, 3154003B 155Gd- CD279 (PD-1), Fluidigm, EH12.2H7, 3155009B 156Gd- CD86, Fluidigm, IT2.2, 3156008B 158Gd- pStat3 [Y705], Fluidigm, 4, 3158005A 159Tb- FoxP3, Fluidigm, 236A/E7, Custom made 160Gd- Tbet, Fluidigm, 4B10, 3160010B 161Dy- CD152 (CTLA-4), Fluidigm, 14D3, 3161004B 162Dy- CD80 (B7-1), Fluidigm, 2D10.4, 3162010B 163Dy- CD183 (CXCR3), Fluidigm, G025H7, 3163004B 164Dy- CD185 (CXCR5), Fluidigm, 51505, 3164016B 3 n atu re p o rtfo lio | rep o rtin g su m m ary M a rch 2021 Validation Eukaryotic cell lines Policy information about cell lines Cell line source(s) Authentication Mycoplasma contamination Commonly misidentified lines (See ICLAC register) Animals and other organisms Policy information about studies involving animals; ARRIVE guidelines recommended for reporting animal research Laboratory animals Wild animals Field-collected samples Ethics oversight Note that full information on the approval of the study protocol must also be provided in the manuscript.
Article Title: Visualization of Mass Cytometry Signal Background to Enable Optimal Core Panel Customization and Signal Threshold Gating.
Article Snippet: Signal interference or overlap in mass cytometry is minimal compared to flow cytometry but must still be considered for optimal panel design and assay sensitivity.. Here we describe a procedure for evaluating signal interference dynamics in the context of a 25-parameter core immunophenotyping panel.. Specifically, a massminusmany (MMM) approach was used to assess background signals in “empty” or “blank” channels intended for further customization.
Article Title: Early-to-mid stage idiopathic Parkinson’s disease shows enhanced cytotoxicity and differentiation in CD8 T-cells in females
Article Snippet: Metal Isotope, Antibody, Clone, Manufacturer, Catalogue# 89Y, CD45, HI30, Fluidigm (now Standardbio), Part of MDIPA (cat. 201325) 103Rh, Live/Dead indicator, Fluidigm, Part of MDIPA, 201325 141Pr, CD196 (CCR6), G034E3, Fluidigm, Part of MDIPA, 201325 142Nd, CD117 (c-kit)*, 104D2, Biolegend, 313223 143Nd, CD123, 6H6 ,Fluidigm, Part of MDIPA, 201325 144Nd, CD19, HIB19, Fluidigm, Part of MDIPA, 201325 145Nd, CD4, RPA-T4, Fluidigm, Part of MDIPA, 201325 146Nd, CD8a, RPA-T8, Fluidigm, Part of MDIPA, 201325 147Sm, CD11c, Bu15, Fluidigm, Part of MDIPA, 201325 148Nd, CD16, 3G8, Fluidigm, Part of MDIPA, 201325 149Sm, CD45RO, UCHL1, Fluidigm, Part of MDIPA, 201325 150Nd, CD45RA, HI100, Fluidigm, Part of MDIPA, 201325 151Eu, CD161, HP-3G10, Fluidigm, Part of MDIPA, 201325 152Sm, CD194 (CCR4), L291H4, Fluidigm, Part of MDIPA, 201325 153Eu, CD25, BC96, Fluidigm, Part of MDIPA, 201325 154Sm, CD27, O323, Fluidigm, Part of MDIPA, 201325 155Gd, CD57, HCD57, Fluidigm, Part of MDIPA, 201325 156Gd, CD183 (CXCR3), G025H7, Fluidigm, Part of MDIPA, 201325 158Gd, CD185 (CXCR5), J252D4, Fluidigm, Part of MDIPA, 201325 159Tb, KLRG1*, SA231A2, Biolegend, 367702 160Gd, CD28, CD28.2, Fluidigm, Part of MDIPA, 201325 161Dy, CD38, HB-7, Fluidigm, Part of MDIPA, 201325 162Dy, CD336 (NKP44)*, P44-8, Biolegend, 325102 163Dy, CD56 (NCAM), NCAM16.2, Fluidigm, Part of MDIPA, 201325 164Dy, TCRgd, B1, Fluidigm, Part of MDIPA, 201325 165Ho, CD223 (LAG3), 11C3C65, Fluidigm, 3165037B 166Er, CD294, BM16, Fluidigm, Part of MDIPA, 201325 167Er, CD197 (CCR7), G043H7, Fluidigm, Part of MDIPA, 201325 168Er, CD14, 63D3, Fluidigm, Part of MDIPA, 201325 169Tm, CD49d*, 9F10, Biolegend, 304302 170Er, CD3, UCHT1, Fluidigm, Part of MDIPA, 201325 171Yb, CD20, 2H7, Fluidigm, Part of MDIPA, 201325 172Yb, CD66b, G10F5, Fluidigm, Part of MDIPA, 201325 173Yb, HLA-DR, LN3, Fluidigm, Part of MDIPA, 201325 174Yb, IgD, IA6-2, Fluidigm, Part of MDIPA, 201325 175Lu, CD279 (PD-1), EH12.2H7, Fluidigm, 3175008B, 201325 176Yb, CD127, A019D5, Fluidigm, Part of MDIPA, 201325 * in-house conjugation using Maxpar X8 Antibody Labeling Kits MDIPA (201325, Fluidigm).
Software:Article Title: Depletion of central memory CD8 + T cells might impede the antitumor therapeutic effect of Mogamulizumab
Article Snippet: CyTOF: 141Pr- EOMES, Fluidigm, WD1928, Custom made 142Nd- CD40, Fluidigm, 5C3, 3142010B 143Nd- CD45RA, Fluidigm, HI100, 3143006B 146Nd- CD8a, Fluidigm, RPA-T8, 3146001B 147Sm- CD11c, Fluidigm, Bu15, 3147008B 148Nd- CD14, Fluidigm, RMO52, 3148010B 149Sm- pLck [T505], Fluidigm, 4/LCK-Y505, Custom made 150Nd- CD134 (OX40), Fluidigm, ACT35, 3150023B 151Eu- CD107a (LAMP1), Fluidigm, H4A3, 3151002B 153Eu- CD194 (CCR4), Fluidigm, 205410, 3153013A 154Sm- CD3, Fluidigm, UCHT1, 3154003B 155Gd- CD279 (PD-1), Fluidigm, EH12.2H7, 3155009B 156Gd- CD86, Fluidigm, IT2.2, 3156008B 158Gd- pStat3 [Y705], Fluidigm, 4, 3158005A 159Tb- FoxP3, Fluidigm, 236A/E7, Custom made 160Gd- Tbet, Fluidigm, 4B10, 3160010B 161Dy- CD152 (CTLA-4), Fluidigm, 14D3, 3161004B 162Dy- CD80 (B7-1), Fluidigm, 2D10.4, 3162010B 163Dy- CD183 (CXCR3), Fluidigm, G025H7, 3163004B 164Dy- CD185 (CXCR5), Fluidigm, 51505, 3164016B 3 n atu re p o rtfo lio | rep o rtin g su m m ary M a rch 2021 Validation Eukaryotic cell lines Policy information about cell lines Cell line source(s) Authentication Mycoplasma contamination Commonly misidentified lines (See ICLAC register) Animals and other organisms Policy information about studies involving animals; ARRIVE guidelines recommended for reporting animal research Laboratory animals Wild animals Field-collected samples Ethics oversight Note that full information on the approval of the study protocol must also be provided in the manuscript.
Article Title: Visualization of Mass Cytometry Signal Background to Enable Optimal Core Panel Customization and Signal Threshold Gating.
Article Snippet: Signal interference or overlap in mass cytometry is minimal compared to flow cytometry but must still be considered for optimal panel design and assay sensitivity.. Here we describe a procedure for evaluating signal interference dynamics in the context of a 25-parameter core immunophenotyping panel.. Specifically, a massminusmany (MMM) approach was used to assess background signals in “empty” or “blank” channels intended for further customization.
Article Title: Early-to-mid stage idiopathic Parkinson’s disease shows enhanced cytotoxicity and differentiation in CD8 T-cells in females
Article Snippet: Metal Isotope, Antibody, Clone, Manufacturer, Catalogue# 89Y, CD45, HI30, Fluidigm (now Standardbio), Part of MDIPA (cat. 201325) 103Rh, Live/Dead indicator, Fluidigm, Part of MDIPA, 201325 141Pr, CD196 (CCR6), G034E3, Fluidigm, Part of MDIPA, 201325 142Nd, CD117 (c-kit)*, 104D2, Biolegend, 313223 143Nd, CD123, 6H6 ,Fluidigm, Part of MDIPA, 201325 144Nd, CD19, HIB19, Fluidigm, Part of MDIPA, 201325 145Nd, CD4, RPA-T4, Fluidigm, Part of MDIPA, 201325 146Nd, CD8a, RPA-T8, Fluidigm, Part of MDIPA, 201325 147Sm, CD11c, Bu15, Fluidigm, Part of MDIPA, 201325 148Nd, CD16, 3G8, Fluidigm, Part of MDIPA, 201325 149Sm, CD45RO, UCHL1, Fluidigm, Part of MDIPA, 201325 150Nd, CD45RA, HI100, Fluidigm, Part of MDIPA, 201325 151Eu, CD161, HP-3G10, Fluidigm, Part of MDIPA, 201325 152Sm, CD194 (CCR4), L291H4, Fluidigm, Part of MDIPA, 201325 153Eu, CD25, BC96, Fluidigm, Part of MDIPA, 201325 154Sm, CD27, O323, Fluidigm, Part of MDIPA, 201325 155Gd, CD57, HCD57, Fluidigm, Part of MDIPA, 201325 156Gd, CD183 (CXCR3), G025H7, Fluidigm, Part of MDIPA, 201325 158Gd, CD185 (CXCR5), J252D4, Fluidigm, Part of MDIPA, 201325 159Tb, KLRG1*, SA231A2, Biolegend, 367702 160Gd, CD28, CD28.2, Fluidigm, Part of MDIPA, 201325 161Dy, CD38, HB-7, Fluidigm, Part of MDIPA, 201325 162Dy, CD336 (NKP44)*, P44-8, Biolegend, 325102 163Dy, CD56 (NCAM), NCAM16.2, Fluidigm, Part of MDIPA, 201325 164Dy, TCRgd, B1, Fluidigm, Part of MDIPA, 201325 165Ho, CD223 (LAG3), 11C3C65, Fluidigm, 3165037B 166Er, CD294, BM16, Fluidigm, Part of MDIPA, 201325 167Er, CD197 (CCR7), G043H7, Fluidigm, Part of MDIPA, 201325 168Er, CD14, 63D3, Fluidigm, Part of MDIPA, 201325 169Tm, CD49d*, 9F10, Biolegend, 304302 170Er, CD3, UCHT1, Fluidigm, Part of MDIPA, 201325 171Yb, CD20, 2H7, Fluidigm, Part of MDIPA, 201325 172Yb, CD66b, G10F5, Fluidigm, Part of MDIPA, 201325 173Yb, HLA-DR, LN3, Fluidigm, Part of MDIPA, 201325 174Yb, IgD, IA6-2, Fluidigm, Part of MDIPA, 201325 175Lu, CD279 (PD-1), EH12.2H7, Fluidigm, 3175008B, 201325 176Yb, CD127, A019D5, Fluidigm, Part of MDIPA, 201325 * in-house conjugation using Maxpar X8 Antibody Labeling Kits MDIPA (201325, Fluidigm).
Recombinase Polymerase Amplification:Article Title: Depletion of central memory CD8 + T cells might impede the antitumor therapeutic effect of Mogamulizumab
Article Snippet: CyTOF: 141Pr- EOMES, Fluidigm, WD1928, Custom made 142Nd- CD40, Fluidigm, 5C3, 3142010B 143Nd- CD45RA, Fluidigm, HI100, 3143006B 146Nd- CD8a, Fluidigm, RPA-T8, 3146001B 147Sm- CD11c, Fluidigm, Bu15, 3147008B 148Nd- CD14, Fluidigm, RMO52, 3148010B 149Sm- pLck [T505], Fluidigm, 4/LCK-Y505, Custom made 150Nd- CD134 (OX40), Fluidigm, ACT35, 3150023B 151Eu- CD107a (LAMP1), Fluidigm, H4A3, 3151002B 153Eu- CD194 (CCR4), Fluidigm, 205410, 3153013A 154Sm- CD3, Fluidigm, UCHT1, 3154003B 155Gd- CD279 (PD-1), Fluidigm, EH12.2H7, 3155009B 156Gd- CD86, Fluidigm, IT2.2, 3156008B 158Gd- pStat3 [Y705], Fluidigm, 4, 3158005A 159Tb- FoxP3, Fluidigm, 236A/E7, Custom made 160Gd- Tbet, Fluidigm, 4B10, 3160010B 161Dy- CD152 (CTLA-4), Fluidigm, 14D3, 3161004B 162Dy- CD80 (B7-1), Fluidigm, 2D10.4, 3162010B 163Dy- CD183 (CXCR3), Fluidigm, G025H7, 3163004B 164Dy- CD185 (CXCR5), Fluidigm, 51505, 3164016B 3 n atu re p o rtfo lio | rep o rtin g su m m ary M a rch 2021 Validation Eukaryotic cell lines Policy information about cell lines Cell line source(s) Authentication Mycoplasma contamination Commonly misidentified lines (See ICLAC register) Animals and other organisms Policy information about studies involving animals; ARRIVE guidelines recommended for reporting animal research Laboratory animals Wild animals Field-collected samples Ethics oversight Note that full information on the approval of the study protocol must also be provided in the manuscript.
Article Title: Visualization of Mass Cytometry Signal Background to Enable Optimal Core Panel Customization and Signal Threshold Gating.
Article Snippet: Signal interference or overlap in mass cytometry is minimal compared to flow cytometry but must still be considered for optimal panel design and assay sensitivity.. Here we describe a procedure for evaluating signal interference dynamics in the context of a 25-parameter core immunophenotyping panel.. Specifically, a massminusmany (MMM) approach was used to assess background signals in “empty” or “blank” channels intended for further customization.
Article Title: Early-to-mid stage idiopathic Parkinson’s disease shows enhanced cytotoxicity and differentiation in CD8 T-cells in females
Article Snippet: Metal Isotope, Antibody, Clone, Manufacturer, Catalogue# 89Y, CD45, HI30, Fluidigm (now Standardbio), Part of MDIPA (cat. 201325) 103Rh, Live/Dead indicator, Fluidigm, Part of MDIPA, 201325 141Pr, CD196 (CCR6), G034E3, Fluidigm, Part of MDIPA, 201325 142Nd, CD117 (c-kit)*, 104D2, Biolegend, 313223 143Nd, CD123, 6H6 ,Fluidigm, Part of MDIPA, 201325 144Nd, CD19, HIB19, Fluidigm, Part of MDIPA, 201325 145Nd, CD4, RPA-T4, Fluidigm, Part of MDIPA, 201325 146Nd, CD8a, RPA-T8, Fluidigm, Part of MDIPA, 201325 147Sm, CD11c, Bu15, Fluidigm, Part of MDIPA, 201325 148Nd, CD16, 3G8, Fluidigm, Part of MDIPA, 201325 149Sm, CD45RO, UCHL1, Fluidigm, Part of MDIPA, 201325 150Nd, CD45RA, HI100, Fluidigm, Part of MDIPA, 201325 151Eu, CD161, HP-3G10, Fluidigm, Part of MDIPA, 201325 152Sm, CD194 (CCR4), L291H4, Fluidigm, Part of MDIPA, 201325 153Eu, CD25, BC96, Fluidigm, Part of MDIPA, 201325 154Sm, CD27, O323, Fluidigm, Part of MDIPA, 201325 155Gd, CD57, HCD57, Fluidigm, Part of MDIPA, 201325 156Gd, CD183 (CXCR3), G025H7, Fluidigm, Part of MDIPA, 201325 158Gd, CD185 (CXCR5), J252D4, Fluidigm, Part of MDIPA, 201325 159Tb, KLRG1*, SA231A2, Biolegend, 367702 160Gd, CD28, CD28.2, Fluidigm, Part of MDIPA, 201325 161Dy, CD38, HB-7, Fluidigm, Part of MDIPA, 201325 162Dy, CD336 (NKP44)*, P44-8, Biolegend, 325102 163Dy, CD56 (NCAM), NCAM16.2, Fluidigm, Part of MDIPA, 201325 164Dy, TCRgd, B1, Fluidigm, Part of MDIPA, 201325 165Ho, CD223 (LAG3), 11C3C65, Fluidigm, 3165037B 166Er, CD294, BM16, Fluidigm, Part of MDIPA, 201325 167Er, CD197 (CCR7), G043H7, Fluidigm, Part of MDIPA, 201325 168Er, CD14, 63D3, Fluidigm, Part of MDIPA, 201325 169Tm, CD49d*, 9F10, Biolegend, 304302 170Er, CD3, UCHT1, Fluidigm, Part of MDIPA, 201325 171Yb, CD20, 2H7, Fluidigm, Part of MDIPA, 201325 172Yb, CD66b, G10F5, Fluidigm, Part of MDIPA, 201325 173Yb, HLA-DR, LN3, Fluidigm, Part of MDIPA, 201325 174Yb, IgD, IA6-2, Fluidigm, Part of MDIPA, 201325 175Lu, CD279 (PD-1), EH12.2H7, Fluidigm, 3175008B, 201325 176Yb, CD127, A019D5, Fluidigm, Part of MDIPA, 201325 * in-house conjugation using Maxpar X8 Antibody Labeling Kits MDIPA (201325, Fluidigm).
Conjugation Assay:Article Title: Depletion of central memory CD8 + T cells might impede the antitumor therapeutic effect of Mogamulizumab
Article Snippet: CyTOF: 141Pr- EOMES, Fluidigm, WD1928, Custom made 142Nd- CD40, Fluidigm, 5C3, 3142010B 143Nd- CD45RA, Fluidigm, HI100, 3143006B 146Nd- CD8a, Fluidigm, RPA-T8, 3146001B 147Sm- CD11c, Fluidigm, Bu15, 3147008B 148Nd- CD14, Fluidigm, RMO52, 3148010B 149Sm- pLck [T505], Fluidigm, 4/LCK-Y505, Custom made 150Nd- CD134 (OX40), Fluidigm, ACT35, 3150023B 151Eu- CD107a (LAMP1), Fluidigm, H4A3, 3151002B 153Eu- CD194 (CCR4), Fluidigm, 205410, 3153013A 154Sm- CD3, Fluidigm, UCHT1, 3154003B 155Gd- CD279 (PD-1), Fluidigm, EH12.2H7, 3155009B 156Gd- CD86, Fluidigm, IT2.2, 3156008B 158Gd- pStat3 [Y705], Fluidigm, 4, 3158005A 159Tb- FoxP3, Fluidigm, 236A/E7, Custom made 160Gd- Tbet, Fluidigm, 4B10, 3160010B 161Dy- CD152 (CTLA-4), Fluidigm, 14D3, 3161004B 162Dy- CD80 (B7-1), Fluidigm, 2D10.4, 3162010B 163Dy- CD183 (CXCR3), Fluidigm, G025H7, 3163004B 164Dy- CD185 (CXCR5), Fluidigm, 51505, 3164016B 3 n atu re p o rtfo lio | rep o rtin g su m m ary M a rch 2021 Validation Eukaryotic cell lines Policy information about cell lines Cell line source(s) Authentication Mycoplasma contamination Commonly misidentified lines (See ICLAC register) Animals and other organisms Policy information about studies involving animals; ARRIVE guidelines recommended for reporting animal research Laboratory animals Wild animals Field-collected samples Ethics oversight Note that full information on the approval of the study protocol must also be provided in the manuscript.
Article Title: Visualization of Mass Cytometry Signal Background to Enable Optimal Core Panel Customization and Signal Threshold Gating.
Article Snippet: Signal interference or overlap in mass cytometry is minimal compared to flow cytometry but must still be considered for optimal panel design and assay sensitivity.. Here we describe a procedure for evaluating signal interference dynamics in the context of a 25-parameter core immunophenotyping panel.. Specifically, a massminusmany (MMM) approach was used to assess background signals in “empty” or “blank” channels intended for further customization.
Article Title: Early-to-mid stage idiopathic Parkinson’s disease shows enhanced cytotoxicity and differentiation in CD8 T-cells in females
Article Snippet: Metal Isotope, Antibody, Clone, Manufacturer, Catalogue# 89Y, CD45, HI30, Fluidigm (now Standardbio), Part of MDIPA (cat. 201325) 103Rh, Live/Dead indicator, Fluidigm, Part of MDIPA, 201325 141Pr, CD196 (CCR6), G034E3, Fluidigm, Part of MDIPA, 201325 142Nd, CD117 (c-kit)*, 104D2, Biolegend, 313223 143Nd, CD123, 6H6 ,Fluidigm, Part of MDIPA, 201325 144Nd, CD19, HIB19, Fluidigm, Part of MDIPA, 201325 145Nd, CD4, RPA-T4, Fluidigm, Part of MDIPA, 201325 146Nd, CD8a, RPA-T8, Fluidigm, Part of MDIPA, 201325 147Sm, CD11c, Bu15, Fluidigm, Part of MDIPA, 201325 148Nd, CD16, 3G8, Fluidigm, Part of MDIPA, 201325 149Sm, CD45RO, UCHL1, Fluidigm, Part of MDIPA, 201325 150Nd, CD45RA, HI100, Fluidigm, Part of MDIPA, 201325 151Eu, CD161, HP-3G10, Fluidigm, Part of MDIPA, 201325 152Sm, CD194 (CCR4), L291H4, Fluidigm, Part of MDIPA, 201325 153Eu, CD25, BC96, Fluidigm, Part of MDIPA, 201325 154Sm, CD27, O323, Fluidigm, Part of MDIPA, 201325 155Gd, CD57, HCD57, Fluidigm, Part of MDIPA, 201325 156Gd, CD183 (CXCR3), G025H7, Fluidigm, Part of MDIPA, 201325 158Gd, CD185 (CXCR5), J252D4, Fluidigm, Part of MDIPA, 201325 159Tb, KLRG1*, SA231A2, Biolegend, 367702 160Gd, CD28, CD28.2, Fluidigm, Part of MDIPA, 201325 161Dy, CD38, HB-7, Fluidigm, Part of MDIPA, 201325 162Dy, CD336 (NKP44)*, P44-8, Biolegend, 325102 163Dy, CD56 (NCAM), NCAM16.2, Fluidigm, Part of MDIPA, 201325 164Dy, TCRgd, B1, Fluidigm, Part of MDIPA, 201325 165Ho, CD223 (LAG3), 11C3C65, Fluidigm, 3165037B 166Er, CD294, BM16, Fluidigm, Part of MDIPA, 201325 167Er, CD197 (CCR7), G043H7, Fluidigm, Part of MDIPA, 201325 168Er, CD14, 63D3, Fluidigm, Part of MDIPA, 201325 169Tm, CD49d*, 9F10, Biolegend, 304302 170Er, CD3, UCHT1, Fluidigm, Part of MDIPA, 201325 171Yb, CD20, 2H7, Fluidigm, Part of MDIPA, 201325 172Yb, CD66b, G10F5, Fluidigm, Part of MDIPA, 201325 173Yb, HLA-DR, LN3, Fluidigm, Part of MDIPA, 201325 174Yb, IgD, IA6-2, Fluidigm, Part of MDIPA, 201325 175Lu, CD279 (PD-1), EH12.2H7, Fluidigm, 3175008B, 201325 176Yb, CD127, A019D5, Fluidigm, Part of MDIPA, 201325 * in-house conjugation using Maxpar X8 Antibody Labeling Kits MDIPA (201325, Fluidigm).
Antibody Labeling:Article Title: Depletion of central memory CD8 + T cells might impede the antitumor therapeutic effect of Mogamulizumab
Article Snippet: CyTOF: 141Pr- EOMES, Fluidigm, WD1928, Custom made 142Nd- CD40, Fluidigm, 5C3, 3142010B 143Nd- CD45RA, Fluidigm, HI100, 3143006B 146Nd- CD8a, Fluidigm, RPA-T8, 3146001B 147Sm- CD11c, Fluidigm, Bu15, 3147008B 148Nd- CD14, Fluidigm, RMO52, 3148010B 149Sm- pLck [T505], Fluidigm, 4/LCK-Y505, Custom made 150Nd- CD134 (OX40), Fluidigm, ACT35, 3150023B 151Eu- CD107a (LAMP1), Fluidigm, H4A3, 3151002B 153Eu- CD194 (CCR4), Fluidigm, 205410, 3153013A 154Sm- CD3, Fluidigm, UCHT1, 3154003B 155Gd- CD279 (PD-1), Fluidigm, EH12.2H7, 3155009B 156Gd- CD86, Fluidigm, IT2.2, 3156008B 158Gd- pStat3 [Y705], Fluidigm, 4, 3158005A 159Tb- FoxP3, Fluidigm, 236A/E7, Custom made 160Gd- Tbet, Fluidigm, 4B10, 3160010B 161Dy- CD152 (CTLA-4), Fluidigm, 14D3, 3161004B 162Dy- CD80 (B7-1), Fluidigm, 2D10.4, 3162010B 163Dy- CD183 (CXCR3), Fluidigm, G025H7, 3163004B 164Dy- CD185 (CXCR5), Fluidigm, 51505, 3164016B 3 n atu re p o rtfo lio | rep o rtin g su m m ary M a rch 2021 Validation Eukaryotic cell lines Policy information about cell lines Cell line source(s) Authentication Mycoplasma contamination Commonly misidentified lines (See ICLAC register) Animals and other organisms Policy information about studies involving animals; ARRIVE guidelines recommended for reporting animal research Laboratory animals Wild animals Field-collected samples Ethics oversight Note that full information on the approval of the study protocol must also be provided in the manuscript.
Article Title: Visualization of Mass Cytometry Signal Background to Enable Optimal Core Panel Customization and Signal Threshold Gating.
Article Snippet: Signal interference or overlap in mass cytometry is minimal compared to flow cytometry but must still be considered for optimal panel design and assay sensitivity.. Here we describe a procedure for evaluating signal interference dynamics in the context of a 25-parameter core immunophenotyping panel.. Specifically, a massminusmany (MMM) approach was used to assess background signals in “empty” or “blank” channels intended for further customization.
Article Title: Early-to-mid stage idiopathic Parkinson’s disease shows enhanced cytotoxicity and differentiation in CD8 T-cells in females
Article Snippet: Metal Isotope, Antibody, Clone, Manufacturer, Catalogue# 89Y, CD45, HI30, Fluidigm (now Standardbio), Part of MDIPA (cat. 201325) 103Rh, Live/Dead indicator, Fluidigm, Part of MDIPA, 201325 141Pr, CD196 (CCR6), G034E3, Fluidigm, Part of MDIPA, 201325 142Nd, CD117 (c-kit)*, 104D2, Biolegend, 313223 143Nd, CD123, 6H6 ,Fluidigm, Part of MDIPA, 201325 144Nd, CD19, HIB19, Fluidigm, Part of MDIPA, 201325 145Nd, CD4, RPA-T4, Fluidigm, Part of MDIPA, 201325 146Nd, CD8a, RPA-T8, Fluidigm, Part of MDIPA, 201325 147Sm, CD11c, Bu15, Fluidigm, Part of MDIPA, 201325 148Nd, CD16, 3G8, Fluidigm, Part of MDIPA, 201325 149Sm, CD45RO, UCHL1, Fluidigm, Part of MDIPA, 201325 150Nd, CD45RA, HI100, Fluidigm, Part of MDIPA, 201325 151Eu, CD161, HP-3G10, Fluidigm, Part of MDIPA, 201325 152Sm, CD194 (CCR4), L291H4, Fluidigm, Part of MDIPA, 201325 153Eu, CD25, BC96, Fluidigm, Part of MDIPA, 201325 154Sm, CD27, O323, Fluidigm, Part of MDIPA, 201325 155Gd, CD57, HCD57, Fluidigm, Part of MDIPA, 201325 156Gd, CD183 (CXCR3), G025H7, Fluidigm, Part of MDIPA, 201325 158Gd, CD185 (CXCR5), J252D4, Fluidigm, Part of MDIPA, 201325 159Tb, KLRG1*, SA231A2, Biolegend, 367702 160Gd, CD28, CD28.2, Fluidigm, Part of MDIPA, 201325 161Dy, CD38, HB-7, Fluidigm, Part of MDIPA, 201325 162Dy, CD336 (NKP44)*, P44-8, Biolegend, 325102 163Dy, CD56 (NCAM), NCAM16.2, Fluidigm, Part of MDIPA, 201325 164Dy, TCRgd, B1, Fluidigm, Part of MDIPA, 201325 165Ho, CD223 (LAG3), 11C3C65, Fluidigm, 3165037B 166Er, CD294, BM16, Fluidigm, Part of MDIPA, 201325 167Er, CD197 (CCR7), G043H7, Fluidigm, Part of MDIPA, 201325 168Er, CD14, 63D3, Fluidigm, Part of MDIPA, 201325 169Tm, CD49d*, 9F10, Biolegend, 304302 170Er, CD3, UCHT1, Fluidigm, Part of MDIPA, 201325 171Yb, CD20, 2H7, Fluidigm, Part of MDIPA, 201325 172Yb, CD66b, G10F5, Fluidigm, Part of MDIPA, 201325 173Yb, HLA-DR, LN3, Fluidigm, Part of MDIPA, 201325 174Yb, IgD, IA6-2, Fluidigm, Part of MDIPA, 201325 175Lu, CD279 (PD-1), EH12.2H7, Fluidigm, 3175008B, 201325 176Yb, CD127, A019D5, Fluidigm, Part of MDIPA, 201325 * in-house conjugation using Maxpar X8 Antibody Labeling Kits MDIPA (201325, Fluidigm).
Biomarker Discovery:Article Title: Depletion of central memory CD8 + T cells might impede the antitumor therapeutic effect of Mogamulizumab
Article Snippet: CyTOF: 141Pr- EOMES, Fluidigm, WD1928, Custom made 142Nd- CD40, Fluidigm, 5C3, 3142010B 143Nd- CD45RA, Fluidigm, HI100, 3143006B 146Nd- CD8a, Fluidigm, RPA-T8, 3146001B 147Sm- CD11c, Fluidigm, Bu15, 3147008B 148Nd- CD14, Fluidigm, RMO52, 3148010B 149Sm- pLck [T505], Fluidigm, 4/LCK-Y505, Custom made 150Nd- CD134 (OX40), Fluidigm, ACT35, 3150023B 151Eu- CD107a (LAMP1), Fluidigm, H4A3, 3151002B 153Eu- CD194 (CCR4), Fluidigm, 205410, 3153013A 154Sm- CD3, Fluidigm, UCHT1, 3154003B 155Gd- CD279 (PD-1), Fluidigm, EH12.2H7, 3155009B 156Gd- CD86, Fluidigm, IT2.2, 3156008B 158Gd- pStat3 [Y705], Fluidigm, 4, 3158005A 159Tb- FoxP3, Fluidigm, 236A/E7, Custom made 160Gd- Tbet, Fluidigm, 4B10, 3160010B 161Dy- CD152 (CTLA-4), Fluidigm, 14D3, 3161004B 162Dy- CD80 (B7-1), Fluidigm, 2D10.4, 3162010B 163Dy- CD183 (CXCR3), Fluidigm, G025H7, 3163004B 164Dy- CD185 (CXCR5), Fluidigm, 51505, 3164016B 3 n atu re p o rtfo lio | rep o rtin g su m m ary M a rch 2021 Validation Eukaryotic cell lines Policy information about cell lines Cell line source(s) Authentication Mycoplasma contamination Commonly misidentified lines (See ICLAC register) Animals and other organisms Policy information about studies involving animals; ARRIVE guidelines recommended for reporting animal research Laboratory animals Wild animals Field-collected samples Ethics oversight Note that full information on the approval of the study protocol must also be provided in the manuscript.
Article Title: Visualization of Mass Cytometry Signal Background to Enable Optimal Core Panel Customization and Signal Threshold Gating.
Article Snippet: Signal interference or overlap in mass cytometry is minimal compared to flow cytometry but must still be considered for optimal panel design and assay sensitivity.. Here we describe a procedure for evaluating signal interference dynamics in the context of a 25-parameter core immunophenotyping panel.. Specifically, a massminusmany (MMM) approach was used to assess background signals in “empty” or “blank” channels intended for further customization.
Article Title: Early-to-mid stage idiopathic Parkinson’s disease shows enhanced cytotoxicity and differentiation in CD8 T-cells in females
Article Snippet: Metal Isotope, Antibody, Clone, Manufacturer, Catalogue# 89Y, CD45, HI30, Fluidigm (now Standardbio), Part of MDIPA (cat. 201325) 103Rh, Live/Dead indicator, Fluidigm, Part of MDIPA, 201325 141Pr, CD196 (CCR6), G034E3, Fluidigm, Part of MDIPA, 201325 142Nd, CD117 (c-kit)*, 104D2, Biolegend, 313223 143Nd, CD123, 6H6 ,Fluidigm, Part of MDIPA, 201325 144Nd, CD19, HIB19, Fluidigm, Part of MDIPA, 201325 145Nd, CD4, RPA-T4, Fluidigm, Part of MDIPA, 201325 146Nd, CD8a, RPA-T8, Fluidigm, Part of MDIPA, 201325 147Sm, CD11c, Bu15, Fluidigm, Part of MDIPA, 201325 148Nd, CD16, 3G8, Fluidigm, Part of MDIPA, 201325 149Sm, CD45RO, UCHL1, Fluidigm, Part of MDIPA, 201325 150Nd, CD45RA, HI100, Fluidigm, Part of MDIPA, 201325 151Eu, CD161, HP-3G10, Fluidigm, Part of MDIPA, 201325 152Sm, CD194 (CCR4), L291H4, Fluidigm, Part of MDIPA, 201325 153Eu, CD25, BC96, Fluidigm, Part of MDIPA, 201325 154Sm, CD27, O323, Fluidigm, Part of MDIPA, 201325 155Gd, CD57, HCD57, Fluidigm, Part of MDIPA, 201325 156Gd, CD183 (CXCR3), G025H7, Fluidigm, Part of MDIPA, 201325 158Gd, CD185 (CXCR5), J252D4, Fluidigm, Part of MDIPA, 201325 159Tb, KLRG1*, SA231A2, Biolegend, 367702 160Gd, CD28, CD28.2, Fluidigm, Part of MDIPA, 201325 161Dy, CD38, HB-7, Fluidigm, Part of MDIPA, 201325 162Dy, CD336 (NKP44)*, P44-8, Biolegend, 325102 163Dy, CD56 (NCAM), NCAM16.2, Fluidigm, Part of MDIPA, 201325 164Dy, TCRgd, B1, Fluidigm, Part of MDIPA, 201325 165Ho, CD223 (LAG3), 11C3C65, Fluidigm, 3165037B 166Er, CD294, BM16, Fluidigm, Part of MDIPA, 201325 167Er, CD197 (CCR7), G043H7, Fluidigm, Part of MDIPA, 201325 168Er, CD14, 63D3, Fluidigm, Part of MDIPA, 201325 169Tm, CD49d*, 9F10, Biolegend, 304302 170Er, CD3, UCHT1, Fluidigm, Part of MDIPA, 201325 171Yb, CD20, 2H7, Fluidigm, Part of MDIPA, 201325 172Yb, CD66b, G10F5, Fluidigm, Part of MDIPA, 201325 173Yb, HLA-DR, LN3, Fluidigm, Part of MDIPA, 201325 174Yb, IgD, IA6-2, Fluidigm, Part of MDIPA, 201325 175Lu, CD279 (PD-1), EH12.2H7, Fluidigm, 3175008B, 201325 176Yb, CD127, A019D5, Fluidigm, Part of MDIPA, 201325 * in-house conjugation using Maxpar X8 Antibody Labeling Kits MDIPA (201325, Fluidigm).
|
fluidigm is a verified supplier 
fluidigm manufactures this product 